Stock AnalizEdwards Lifesciences (EW) earnings for the quarter ended September 2026: EPS beats estimates
Edwards Lifesciences reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $0.80 against the analysts’ average forecast of $0.74, a beat of 8.6%.
Revenue for the quarter was $1.72 billion, up 10.5% from $1.55 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 5.9% on the first trading day after the report.
The last four quarters
Edwards Lifesciences has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.80 | $0.74 | +8.6% | +10% | +5.9% |
| Jun 2026 | $0.78 | $0.74 | +5.2% | +14% | −2.1% |
| Mar 2026 | $0.78 | $0.73 | +7.3% | +17% | +3.2% |
| Sep 2025 | $0.67 | $0.59 | +12.6% | +15% | −0.3% |
What comes next
Analysts expect EPS of $0.66 for the next quarter on average and $3.01 for the fiscal year ending December 31, 2026.
The average analyst price target is $113.24, 6% above the current price of $107.15.
Valuation and score
Edwards Lifesciences scores 2.8 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 60.5, and its intrinsic value under moderate assumptions is about 64% below the current market value. Full Edwards Lifesciences analysis with 10 years of financials
Frequently asked questions
What was Edwards Lifesciences’s EPS for the quarter ended September 2026?
$0.80 adjusted per share, against an analyst consensus of $0.74.
How much revenue did Edwards Lifesciences report?
$1.72 billion, up 10.5% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.